Celiac Disease Panel-Comprehensive : 1000180

CELIAC or 1000180

Celiac Testing; SPRUE; tTG; tTa; Gliadin G; Gliadin A; Failure to Thrive; Gluten Sensitive

Panel includes: Deamidated Gliadin IgA, Deamidated Gliadin IgG, Tissue Transglutaminase IgA, Tissue Transglutaminase IgG, and Endomysial IgA antibodies.If the Endomysial IgA screen is positive, a titer will be performed at an additional charge (CPT code(s): 86231).

Serum separator tube (gold top preferred) or a plain red top tube.

Centrifuge the serum separator tube and transport; if a plain red top tube, centrifuge and aliquot serum (Min. 1.0 mL) into a standard transport tube.

Refrigerated.

After separation from cells: Ambient: 4 days; Refrigerated: 7 days; Frozen: 30 days

Monday & Thursday

1-4 days

This FDA approved test is a semi-quantitative measurement of IgA/IgG. The numeric result or titer may not correlate with state or severity of disease.

For Gliadin Deamidated IgG/IgA::  less than 15.0 U/mL

For tTG IgG/IgA: less than 15.00 U/mL
  
For Endomysial IgA:
Negative (screened at 1:10 dilution)
A titer will be reported from 1:10 to 1:640 if result is Positive.

Celiac disease (CD) is a life-long condition in which the ingestion of gluten leads to chronic inflammation and damage of the small intestinal mucosa. When used in conjunction with clinical symptoms and history, tests for antibodies may be useful in screening for CD or aid in monitoring adherence to a gluten-free diet.  Celiac disease is associated with various autoantibodies, including endomysial, tissue transglutaminase (tTG), and deamidated gliadin antibodies. Usually the IgA isotype of these antibodies predominates in celiac disease; however, individuals may also produce IgG isotypes, particularly if the individual is IgA deficient. The most sensitive and specific serologic tests are tTG and Deamidated Gliadin antibodies.